Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of High Daily Dose Short Course Primaquine After G6PD Testing for the Radical Cure of Plasmodium Vivax Malaria

NCT05874271 is registered in ClinicalTrials.gov with Macfarlane Burnet Institute for Medical Research and Public Health Ltd as lead sponsor.

NCT NCT05874271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05874271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of High Daily Dose Short Course Primaquine After G6PD Testing for the Radical Cure of Plasmodium Vivax Malaria
Lead sponsor
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Phase
Not applicable
Overall status
Completed
Start date
August 7, 2023
Completion date
October 25, 2025
Enrollment
794 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

g6pd deficiency, vivax malaria